ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA

被引：20

作者：

Gettinger, S. ^{[1
]}

Bazhenova, L. ^{[2
]}

Salgia, R. ^{[3
]}

Langer, C. ^{[4
]}

Gold, K. ^{[5
]}

Rosell, R. ^{[6
]}

Shaw, A. ^{[7
]}

Weiss, G. J. ^{[8
]}

Narasimhan, N. I. ^{[9
]}

Dorer, D. J. ^{[10
]}

Rivera, V. M. ^{[11
]}

Clackson, T. ^{[12
]}

Haluska, F. G. ^{[13
]}

Camidge, R. ^{[14
]}

机构：

[1] Yale Univ, Sch Med, Thorac Oncol Program, New Haven, CT USA

[2] UCSD Moores Canc Ctr, La Jolla, CA USA

[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA

[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] USP Dexeus Univ Inst, Inst Oncol Dr Rosell, Med Oncol Serv, Barcelona, Spain

[7] Massachusetts Gen Hosp, Boston, MA 02114 USA

[8] Scottsdale Healthcare, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA

[9] ARIAD Pharmaceut Inc, DMPK, Cambridge, MA USA

[10] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA USA

[11] ARIAD Pharmaceut, Preclin & Translat Res, Cambridge, MA USA

[12] ARIAD Pharmaceut Inc, Res & Dev, Cambridge, MA USA

[13] ARIAD Pharmaceut Inc, Clin Res & Dev, Cambridge, MA USA

[14] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA

来源：

关键词：

D O I：

10.1093/annonc/mdu349.71

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1292P

引用

页数：1